

A Decade of Advances in Treatment of Early-Stage Lung Cancer

Luca Paoletti, MD^a, Nicholas J. Pastis, MD^a,
Chadrick E. Denlinger, MD^b, Gerard A. Silvestri, MD, MS^{a,*}

KEYWORDS

• Lung cancer • Treatment • Surgery • VATS • Elderly

Early-stage non-small cell lung cancer (NSCLC) refers to stage I or stage II disease. Although patients with lung cancer who meet this criterion have the highest 5-year survival and lowest recurrence rates, their prognosis is still poor relative to other early-stage cancers. In patients with early-stage NSCLC, the ability to achieve complete surgical resection remains the most definitive treatment in current medical practice. Surgically resected stage I NSCLC has only a 70% 5-year survival and a 55% to 75% recurrence rate.¹⁻⁴ Five-year survival rates after surgical resection decrease to 40% to 50% for stage II disease.⁵ The large database informing the most recent international lung cancer staging system demonstrated 5-year survival rates for stages IA, IB, IIA, and IIB of 73%, 58%, 46%, and 36%, respectively.⁴ Unfortunately, lung cancer is detected in an advanced stage in approximately 70% of patients, making it one of the leading causes of death in America, with only a 16% overall 5-year survival rate.⁶

The past decade has witnessed a litany of advances in the treatment of early-stage lung cancer. In the past, patients who were inoperable due to poor lung function were relegated to few options with dismal survival results. Now, more options are available, including technologic advances in chest radiotherapy, a growing interest in the utility of sublobar resections, and an increase in the use of video-assisted thoracoscopic surgery (VATS).

Lung cancer screening has also undergone significant change during the past decade. The National Lung Screening Trial compared chest radiograph with low-dose helical chest CT in screening for lung cancer in 53,000 older patients with extensive (>30 pack-year) smoking history. The trial was stopped early due to a 20% reduction in lung cancer death among patients screened with CT scan compared with those screened with chest radiograph.⁷ In the trial, the majority of patients was diagnosed at early stage; 93% of patients with stage I lung cancer detected by CT scan and 88% of patients with stage I lung cancer detected by chest radiograph underwent surgery with curative intent.⁷

One of the most important advances during the past decade was the development and implementation of the 7th edition of the international lung cancer stage classification system. The effect of tumor size on survival was studied in detail and incorporated in defining the new T descriptors. Additional size criteria for primary tumors (2, 5, and 7 cm) further subdivide previous cutoff values. T1 is now divided into T1a (≤ 2 cm) and T1b (>2 cm but ≤ 3 cm). T2 is divided into T2a (>3 cm but ≤ 5 cm) and T2b (>5 cm but ≤ 7 cm). Tumors greater than 7 cm are now considered T3 because this group of patients have survival rates comparable to other definitions of T3.⁴

There is a growing recognition that smaller tumors (≤ 2 cm) have a more favorable prognosis,

The authors have nothing to disclose.

^a Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 812, Charleston, SC 29425, USA

^b Division of Surgery, Medical University of South Carolina, Ashley River Tower, 25 Courtenay Drive, MSC 295, Charleston, SC 29425, USA

* Corresponding author.

E-mail address: silvestr@muscc.edu

Clin Chest Med 32 (2011) 827–838

doi:[10.1016/j.ccm.2011.08.009](https://doi.org/10.1016/j.ccm.2011.08.009)

0272-5231/11/\$ – see front matter © 2011 Elsevier Inc. All rights reserved.

prompting an increased consideration of sublobar as opposed to lobar resections for this group. Additionally, the past decade has witnessed the development and application of lung stereotactic radiation in nonsurgical candidates as well as the demonstration of benefit of adjuvant chemotherapy in patients with large stage IB and stage II NSCLC.⁸

LOBECTOMY VERSUS SUBLOBAR RESECTION

The first lung cancer surgeries involved complete pneumonectomies and frequently resulted in death.⁹ As technology improved, surgery has evolved and become vastly safer and more effective. Patients now have additional surgical options, including lobectomy (the surgical removal of one complete lobe and its lymph nodes) and sublobar resection (anatomic segmentectomy or wedge resection). The surgical approach may be open thoracotomy or VATS. Despite the advances in surgery for early-stage lung cancer over the past decade, questions remain, such as whether lobectomy is uniformly superior to sublobar resection. The two procedures often differ with regard to the extent of parenchymal lymph node sampling and potentially the adequacy of surgical margins. The two procedures also have been associated with different mortality and/or recurrence rates.

Sublobar resections are typically used in patients who have an impaired pulmonary reserve and would not tolerate a full lobectomy. (See the articles by Von Grooten-Bidlingmaier and colleagues and Mehta and colleagues elsewhere in this issue for further discussion of this evaluation.) These procedures can be done via open thoracotomy or VATS.¹⁰ Wedge resections are most often recommended for smaller tumors (<2 cm) that are peripheral in location.¹⁰ The tumor is resected without regard for anatomic bronchial segments and fissures. The benefits are preservation of lung volume and less perioperative morbidity and mortality. The major disadvantages of wedge resection are that N1 (intrapulmonary) lymph node sampling is not possible and that assessment of the surgical margin between staple line and tumor is difficult, leaving open the potential that it may be inadequate. Both of these issues may increase the possibility of higher rates of recurrence.¹¹ Segmentectomy refers to removal of an entire anatomic bronchial segment. It involves a detailed dissection of the bronchial segment and pulmonary arterial supply.^{10,11} Performing a segmentectomy is more of a technical challenge for surgeons; its benefit is that it allows adequate lymph node sampling while preserving lung volume and function.¹¹

In general, lobectomy is considered a superior approach when compared with sublobar resection. Debate continues on this topic, however. The discussion has been muddied by many and often conflicting studies comparing lobectomy with sublobar resections that did not separate the types of sublobar resections (segmentectomy or wedge resection) and that included high-risk patients who underwent sublobar resection because they could not tolerate a lobectomy.

To date, there has been a single prospective randomized study comparing lobectomy with sublobar resection for patients with NSCLC. In 1995, the Lung Cancer Study Group (LCSG) showed that in patients with peripheral early-stage (T1N0) NSCLC, lobectomy was superior to limited resection, which was defined as wedge resection or segmentectomy.¹² The study included 247 patients. In cases in which wedge or segmental resections were performed, there was a 3-fold increase in local recurrence, a 75% increase in combined local and distant recurrence ($P = .02$), and a 50% increase in death in comparison to lobectomies, although this did not reach statistical significance ($P = .09$). Based on this landmark study, the standard of care for individuals with peripheral early-stage NSCLC (T1N0) is lobectomy with lymph node sampling. Subsequent studies have supported the LCSG findings. In a large retrospective review of the Surveillance, Epidemiology, and End Results (SEER) database of 10,761 patients, there was a statistically significant difference in 5-year survival rates for patients who underwent lobectomy versus sublobar resection (61% vs 44%) in patients with stage IA NSCLC.¹³ As with the LCSG study, wedge resection and segmentectomy were combined in this analysis.

Not all studies have concluded that lobectomy is superior to sublobar resection, with some retrospective studies reporting similar survival rates in the two groups. In a series of 784 patients who underwent lung resection for stage I NSCLC, no difference in disease-free survival was noted between patients who had wedge resection or segmentectomy compared with lobectomy.¹⁴ Although there was a difference in 5-year survival favoring lobectomy, the investigators speculated that patients with sublobar resections may have died earlier due to their underlying comorbid diseases, because patients underwent sublobar resection only if they were determined to be high-risk candidates for lobectomy due to decreased cardiopulmonary reserve.¹⁴ Other studies of high-risk patients who underwent sublobar resection instead of lobectomy have had similar results, with 2-year and 5-year survival rates comparable between the two groups.^{15,16} Given that these

studies have been retrospective, and in light of the inconsistent findings in the literature comparing survival between surgical types, lobectomy with lymph node sampling remains the standard of care in patients who are medically fit for such an operation, with sublobar resections typically reserved for situations when lobectomy is not possible.

In some studies where sublobar resection was further separated into segmentectomy and wedge resection, there have been no statistically significant differences in 5-year survival rates between segmentectomy and lobectomy.^{17,18} A recent large single-institution retrospective study comparing anatomic segmentectomy with lobectomy for stage I NSCLC showed no difference in operative morbidity or mortality between the two surgical approaches.¹⁹ Furthermore, there was no difference in overall or disease-free survival between the two groups, although the mean follow-up time seemed limited in the segmentectomy group. A surgical margin of 1 cm seemed important for preventing a local recurrence. In a study evaluating tumor size and survival after various types of surgery, there was no statistical difference between lobectomy and segmentectomy for tumors between 2.1 cm to 3 cm in diameter, with 5-year survival rates of 87% and 85%, respectively.²⁰ For tumors greater than 3 cm, however, lobectomy had a 5-year survival rate of 81% compared with 63% with segmentectomy.²⁰ These findings suggest that segmentectomy may be a reasonable alternative to lobectomy for small early-stage tumors but that lobectomy remains the treatment of choice for larger cancers. In the absence of a randomized trial comparing lobectomy with segmentectomy for treatment of early-stage NSCLC, however, lobectomy remains the standard approach.

In contrast to the findings with anatomic segmentectomy, lobectomy has been shown to have a statistically significant 5-year survival advantage compared with wedge resection.^{12,20,21} This may be in part because surgeons are better able to visualize and remove tumors and lymph nodes with lobectomy than with wedge resection.¹¹

In comparing anatomic segmentectomy with wedge resection, the literature shows that there is a lower rate of cancer recurrence with the former. In an analysis of patients undergoing sublobar resections for early-stage lung cancer, the 5-year survival rate with segmentectomy for tumors less than 2 cm was 96% compared with 85% with wedge resection.²⁰ The difference in 5-year survival was even more evident with tumors between 2.1 cm to 3 cm in size (85% compared with 40%).²⁰

Tumor size thus seems an important factor in the choice of surgical approach for the treatment of early-stage NSCLC. The survival advantage and decrease in recurrence rate associated with a more extensive resection are likely due to a combination of factors. First, the number of lymph nodes that can be sampled varies with the type of surgery. During a segmentectomy, the dissection of the bronchial tree exposes lymph nodes that are routinely resected. Conversely, these intraparenchymal lymph nodes are not visualized or sampled during wedge resection.²² A second factor affecting survival with sublobar resection is the width of the surgical resection margin around the removed tumor. A surgical margin greater than 1 cm is more likely to be achieved with segmentectomy than with wedge resection.²³ To minimize the risk of recurrence, some surgeons advocate that in sublobar resection the surgical margin width should be greater than the tumor diameter.²⁴

In comparing recurrence rates among patients undergoing various degrees of resection for early-stage lung cancer, physicians must continue to refer back to the LCSG study, which identified a 3-fold increase in cancer recurrence with wedge resection and greater than 2-fold increase in recurrence with anatomic segmentectomy compared with lobectomy. Other studies have reported recurrence rates of 2% to 9% with lobectomy compared with 19% to 22% with segmentectomy or wedge resection.^{21,25,26}

It is also important to consider the contribution of adequate mediastinal lymph node evaluation in interpreting outcomes associated with surgical resection of early-stage lung cancer. In patients with stage I NSCLC who underwent sublobar resection (wedge resection or segmentectomy), recurrence rates as high as 50% have been reported in those patients who did not have mediastinal lymphadenectomy compared with 5% in those who did.²⁷ This highlights the importance of the mediastinal lymph node evaluation in patients undergoing curative surgery for early-stage lung cancer.²⁷

In summary, lobectomy with lymphadenectomy is recommended as optimal curative intent therapy for patients with early-stage NSCLC who are appropriate surgical candidates for such a procedure. Sublobar resection, in particular anatomic segmentectomy, should be considered for patients who are suboptimal candidates for lobectomy due to limited pulmonary reserve or other medical comorbidities (**Table 1**). Controversies in this area deserve further study. It is unclear whether lobectomy with lymphadenectomy is superior to anatomic segmentectomy with

Table 1
Advantages and disadvantages of surgeries for early-stage lung cancer

Surgery	Advantages	Disadvantages
1. Lobectomy	<ul style="list-style-type: none"> • Lowest recurrence rate • Entire tumor and lymph nodes removed 	<ul style="list-style-type: none"> • Greater loss of lung function • More extensive and lengthier procedure
2. Segmentectomy	<ul style="list-style-type: none"> • Preservation of lung function • Low recurrence rate • Better tolerated in patients with comorbid medical conditions • Greater number of lymph node dissected than wedge resection • Better surgical margin compared with wedge resection 	<ul style="list-style-type: none"> • Technically challenging • Recurrence rate not clearly equal to lobectomy
3. Wedge resection	<ul style="list-style-type: none"> • Preservation of lung function • Better tolerated in patients with comorbid medical conditions • Shorter operative time 	<ul style="list-style-type: none"> • Highest recurrence rate • Lung tissue removed with disregard to anatomy • Surgical margins may be less sufficient • Cannot remove intrapulmonary (N1) lymph nodes • Mediastinal lymph node dissection often limited or not performed

lymphadenectomy, particularly in patients with small (T1a) tumors, and this is a topic of current active study. A recent report using the SEER database evaluated survival after lobectomy or limited resection in patients with stage IA NSCLC with tumors less than or equal to 1 cm size and found no difference in survival between the two procedures.²⁸ This finding is of particular interest when considering that lung cancer screening with low-dose CT scanning will likely increase the number of these very small cancers that are identified.

VIDEO-ASSISTED THORACOSCOPIC SURGERY

The past decade has seen an increase in the use of VATS for early-stage lung cancer. In 2006, there were approximately 40,000 lobectomies performed, and VATS was used in only 2000 (5%) of those cases.²⁹ This percentage has increased yearly since the initial description of VATS in 1992. Initially VATS was used only for wedge resections; however, as the technology has advanced, more surgeons are increasingly facile with VATS for lobectomy and segmentectomy.

Despite its increasing popularity, there is reluctance among many in the surgical community to change their practice patterns, which may reflect the steep learning curve and technical challenges associated with the VATS approach. There is substantial evidence available demonstrating that VATS lobectomy for early-stage lung cancer is an equivalent oncological operation to lobectomy by open thoracotomy, with equal long-term

survival rates. In addition, many studies have suggested that VATS results in decreased morbidity, decreased length of hospitalization, and a more rapid return to baseline functional levels compared with open procedures. Definitive evidence that VATS is superior to open lobectomy is lacking, however, and changes in practice will likely reflect changing generations of surgeons with more familiarity and training in thoracoscopic surgery rather than the accumulation of such evidence.

There does not seem to be a difference between VATS and open procedures in 5-year survival rates for surgically resected early-stage NSCLC. In the current largest review of a single-center experience that included 1100 patients, McKenna and colleagues²⁹ found that their 5-year survival rate with VATS for early-stage NSCLC was comparable with most contemporary series of patient undergoing open lobectomy. Other single-institution reviews have also shown similar 5-year survival rates between VATS and open lobectomy.³⁰⁻³³ In a multicenter review performed in Japan, the 5-year survival rate for patients with early-stage NSCLC was not statistically significant between the two groups: 97% with open lobectomy versus 96% with VATS.³⁴ Other studies have reported no statistically significant differences in locoregional recurrence with VATS compared with conventional lobectomy.^{29,34,35}

The perioperative mortality rates with VATS and conventional open thoracotomy are similar.^{35,36} Initially, skeptics of VATS questioned whether an adequate lymph node dissection could be

performed, but it is clear that lymph node dissection performed via VATS can be performed as thoroughly as with an open approach.^{37,38} Shortly after the initiation of VATS, a randomized study compared VATS lobectomy with open lobectomy and found no difference in duration of chest tube drainage, length of hospital stay, recovery time, or a decrease in post-thoracotomy pain.³⁹ Since that time, however, several studies have reported significantly shorter hospital length of stay, less postoperative pain and pain medication use, fewer hospital readmissions, shorter recuperation time, shorter chest tube drainage duration, and better preservation of preoperative performance status with VATS.^{34,40–43} The procedure is associated with smaller chest wall incisions and consequently less inflammation, which may contribute to diminished postoperative discomfort and shorter length of stay.³⁴ VATS causes fewer inflammatory markers to be released compared with conventional open lobectomies.^{37,44}

All of the above factors should be considered in choosing the type of surgery to perform for early-stage NSCLC. This may be of particular importance in patients who are anticipated to have treatment with postoperative chemotherapy, because recuperation after surgery often has an impact on the timing of adjuvant therapy. Petersen and colleagues⁴⁵ demonstrated that patients undergoing VATS resections had fewer delays in the delivery of adjuvant chemotherapy and additionally that these patients were more often able to tolerate the prescribed dose of chemotherapy without interruption.

VATS is more likely to be performed in large academic centers with higher surgical volume and dedicated thoracic surgeons.^{36,46} The Society of Thoracic Surgeons is composed of predominantly board-certified thoracic surgeons (220 of the 225 members). In a review of the Society of Thoracic Surgeons database, 22% of all lobectomies in 2004 were performed via VATS, with that percentage increasing to 32% in 2006.⁴⁷ Of all thoracic surgeries in the United States, 36% are performed by general surgeons, who typically do not have extensive training or experience with VATS.⁴⁸ It has been demonstrated that thoracic surgical procedures performed by general surgeons are associated with higher mortality and morbidity, and longer length of stay than are observed with specialty trained thoracic surgeons.^{49,50} The reasons for these differences are likely multifactorial. General surgeons have less exposure and perform fewer thoracic surgeries during their training. In addition, a lower postoperative mortality with lung cancer resection is observed in centers performing a higher volume of cases.^{47,51} Both factors likely contribute

to the lower mortality and morbidity seen in high-volume centers with specialty trained thoracic surgeons.^{36,47,51}

Tumor location and size factor into whether VATS can be feasibly performed. Large tumors (>6 cm in diameter) may necessitate an open approach because of the challenge of manipulating such a bulky tumor with VATS instruments and also because of the practical consideration that a larger incision is required to get a large tumor out of the chest. Although a central tumor location is not necessarily a barrier to a VATS approach, these tumors are often approached with an open thoracotomy because a tactile approach may be needed to ensure adequate surgical margins.

In summary, substantial evidence demonstrates that VATS lobectomy is an appropriate alternative to open lobectomy when performed by experienced hands in centers with adequate thoracic surgical volume. VATS seems to have equivalent oncologic outcomes when compared with open thoracotomy. The decision of which procedure should be chosen for curative intent surgery for early-stage NSCLC should be based on the experience of individual surgeons, the experience of the operating institution, and patient anatomic considerations.

TUMOR SIZE AND SURVIVAL AFTER RESECTION

There is an increased risk of lung cancer mortality with larger tumors, even in patients undergoing successful resection.⁵² Since its inception, TNM staging has served to provide a common descriptive language as well as important prognostic information for patients with solid tumors, including NSCLC.^{53,54} Over the past decade, there has been a great deal of interest in the effect of tumor size, even within the same stage, because there is an association between tumor size and survival.^{4,55–57} Patients with resected small tumors (<2 cm) are well described as having a better 5-year survival than patients whose tumors measure 2.1 cm to 3 cm.¹³ This effect of tumor size on survival was one of the driving forces for change in the lung cancer staging system. The current 7th edition of the TNM staging classification for lung cancer identified new cutpoints for the size of the primary tumor at 2 cm, 3 cm, 5 cm, and 7 cm. Goldstraw and colleagues⁴ reclassified more than 13,000 cases of tumors originally staged by the previous 6th edition of the staging system and demonstrated that median 5-year survival was affected by placement in a different stage. For example, patients who had tumors of 6 cm and no lymph node involvement

were classified as T2N0, stage IB in the old system, with a group 5-year survival of 54%. In the new system, however, these were reclassified as T2bN0, stage IIA, with a group projected 5-year survival of 46%. Tumors greater than 7 cm in diameter with ipsilateral hilar lymph node involvement were staged T2N1, stage IIB in the 6th edition, with a 5-year survival of 38%. In the 7th edition, these tumors would be classified as T3N1 (stage IIIA) with a 5-year survival of 24%. The new changes in the T descriptor in addition to other changes in the staging classification system represent a major advance in lung cancer management and should enhance the ability to more accurately group and characterize patients based on the anatomic description of their cancers.

AGE AND SURVIVAL AFTER RESECTION

Traditionally, lung cancer operations have been avoided in the older geriatric population due to concerns related to the likelihood of increased morbidity and mortality. Some studies have shown a higher mortality rate in elderly patients undergoing surgery for early-stage NSCLC, suggesting that age is an independent predictor of survival.^{13,58} Other studies have demonstrated, however, that lung cancer surgery for elderly patients is a reasonably safe and viable option. As is true for all patients, lung cancer surgical outcomes in older individuals are dependent on their performance status and comorbid conditions.^{59,60} It has been repeatedly demonstrated that elderly patients with good performance status and no comorbid conditions have postoperative outcomes similar to those of their younger counterparts. For example, there was no difference in 5-year survival in 133 Japanese elderly patients (age greater than 75) who underwent either lobectomy or sublobar surgery for stage I NSCLC and also no difference in the postoperative complication rate.^{61,62} Similarly, a study in the Netherlands analyzed approximately 2000 patients over age 80 who were diagnosed with stage I or II NSCLC during a period of 15 years, of whom 6% (124 patients) underwent surgical intervention. The survival rate in the resected patients after 1 year was 83% and after 5 years was 47%, which is comparable with outcomes of surgery in other age demographics in the Netherlands.⁶³ Only a minority of the elderly patients in this study was treated surgically. The fact that they did so well emphasizes that appropriate patient selection is important in optimizing outcomes but also raises the question as to whether more of the elderly patients in that cohort might have benefited from a surgical approach.

Based on these and other studies, there should be no absolute age cutoff for surgery in patients with early-stage NSCLC. This recommendation is clear in the American College of Chest Physicians evidence-based guidelines for lung cancer.⁶⁴ Each case should be individualized, and patient comorbidities, functional status, and personal beliefs taken into account before deciding whether or not surgery is an appropriate recommendation.

SMALL CELL LUNG CANCER

Approximately 13% of all lung cancers diagnosed are SCLC histology.⁶⁵ During the past 10 years, the philosophy of treatment of limited-stage small cell lung cancer (SCLC) has changed (see the article by Neal and colleagues elsewhere in this issue). SCLC tends to progress rapidly and is typically diagnosed after it has metastasized to other sites.⁶⁶ Like NSCLC, SCLC is staged by the TNM paradigm, but the traditional classification of "limited" or "extensive" stage continues to have practical use. Limited-stage SCLC is defined as disease confined to one hemithorax, the mediastinum, and supraclavicular lymph nodes, with the entire extent of disease able to be included in one radiotherapy field. SCLC beyond limited stage is defined as extensive disease. Traditionally, treatment of limited-stage SCLC has been combination chemotherapy and radiation therapy.⁶⁷ Although current guidelines state that there is not enough evidence to categorically offer surgery to limited-stage SCLC patients, consideration is often given to resection with adjuvant chemotherapy for patients who have small tumors and are node negative. In these cases, patients should undergo a thorough evaluation to confirm that disease is truly confined to the primary site, typically with mediastinoscopy, brain imaging, abdominal imaging, and bone scan before surgery.⁶⁸

Yu and colleagues⁶⁹ reviewed 1560 patients with SCLC from the SEER database, of whom 247 underwent lobectomy for stage I disease (primary tumor <3 cm diameter without other disease). Of those, 205 patients did not undergo radiation therapy, with 3-year and 5-year survival rates of 58% and 50%, respectively. There was no difference in survival when compared with patients who did undergo postoperative radiation therapy ($P = .90$).⁶⁹ The median survival of patients who underwent surgery for localized SCLC (defined as T1-T2 NX-N0) was an impressive 65 months, with a 5-year overall survival rate of 52%.⁶⁷ These results suggest that patient with early localized SCLC may benefit from curative intent surgery with adjuvant chemotherapy, with or without radiation therapy.⁶⁵

CHEMOTHERAPY

Treatment regimens involving early-stage NSCLC concentrate on surgical removal of the tumor. In recent years there have been many trials published on the role of adjuvant chemotherapy (4–8 weeks after surgery) for early-stage NSCLC (see the article by Gettinger and Lynch elsewhere in this issue). Before the use of platinum-based chemotherapy there was no survival advantage to adjuvant chemotherapy, so it was not routinely used. More recent studies with the use of platinum-based adjuvant chemotherapy, in particular cisplatin, however, seem to demonstrate a reduction in mortality.⁷⁰

There have been 4 large trials published in the past decade that have confirmed the usefulness of adjuvant chemotherapy in early-stage NSCLC. All of the trials incorporated cisplatin-based chemotherapy regimens. The survival benefit seen in these studies was observed predominantly in stage II lung cancer as opposed to stages IA or IB. The Lung Adjuvant Cisplatin Evaluation (LACE) trial was a meta-analysis of these trials, inclusive of 4500 patients. The LACE trial showed that patients with stage II NSCLC who received adjuvant chemotherapy had a 5% decrease in risk of death at 5 years compared with patients who received no chemotherapy. In contrast, patients with stage IA disease who received chemotherapy had worse outcomes than those who did not receive chemotherapy, and there was no survival advantage in patients with stage IB disease who received chemotherapy.⁷¹

The Adjuvant Navelbine International Trialist Association (ANITA) trial examined the impact of adjuvant chemotherapy in patients with stages IB, II, and III NSCLC.⁷² Stages II and III patients who received adjuvant chemotherapy demonstrated improved survival (66 months compared with 44 months), with an 8.6% increase in overall survival at 5 years compared with those who received no chemotherapy.⁷² This study showed that there was no benefit in using adjuvant chemotherapy in patients with stage IB disease.⁷²

Two other trials, the JBR trial and International Adjuvant Lung Trial (IALT), showed similar results. Both studies demonstrated a survival advantage in patients with stage II disease who received adjuvant chemotherapy as opposed to no chemotherapy.^{73,74} In the JBR trial, patients with stage II disease who received adjuvant chemotherapy had a 5-year survival rate of 59% compared with 44% in those who received no chemotherapy.⁷³

Based on these results, the standard of care in patients with stage II disease is surgical resection followed by adjuvant chemotherapy.⁷⁵ The role of

adjuvant chemotherapy in stage IB lung cancer remains controversial. None of the aforementioned trials found a survival advantage in patients with stage IB who received adjuvant chemotherapy.^{71–74} Another landmark trial, however, cancer and leukemia group B (CALGB) 9633, which examined patients solely with stage IB disease, initially showed a survival advantage in patients who had resection and adjuvant chemotherapy,⁸ and on the basis of this advantage the trial was stopped early. After the ANITA, JBR, and IALT trials failed to confirm this benefit, however, CALGB 9633 was reviewed with more longitudinal data, and no statistical significance in survival after 74 months (ie, beyond the original 5-year survival benchmark) was observed in patients who received chemotherapy compared with those that did not.⁸ A subgroup analysis noted that in patients with tumors greater than 4 cm in size (stage IB), a 31% increase in disease-free survival in patients who received adjuvant chemotherapy compared with those who did not was identified.⁸

To summarize, the recommendation that adjuvant chemotherapy is recommended for patients with stage II NSCLC does represent a substantive change in practice over the past decade. In contrast, the treatment approach for patients with stage IB lung cancer has not changed. The American Society of Clinical Oncology does not recommend adjuvant chemotherapy in these patients.⁷⁵ Based on the results of the CALGB 9633 trial, however, there may be a role for adjuvant chemotherapy in select patients with stage IB NSCLC with large tumors (>4 cm). Furthermore, the new staging system adds a further level of complexity because patients with tumors greater than 5 cm in diameter with no lymph node involvement are now classified as stage IIA; whether or not they may benefit from adjuvant chemotherapy is a subject for future study.

ADVANCES IN CHEST RADIOTHERAPY

Approximately 25% of all patients with early-stage NSCLC are medically inoperable.⁷⁶ Because most patients diagnosed with lung cancer are current or former smokers, many have chronic obstructive pulmonary disease and other medical comorbidities. These patients may be deemed medically inoperable because of projected high rates of complications and death. Patients also may be considered inoperable due to severe heart disease and poor performance status. Patients further may simply decline surgery for personal reasons; these patients are typically treated as if they were medically inoperable. Follow-up of these patients through the SEER database demonstrates that

they have a median survival of 14 months.⁷⁷ The 5-year survival rate of patients treated with supportive care alone is less than 10%.⁷⁸

In the past, the only option for patients who declined surgery or who were medically inoperable was radiation therapy. These patients were given 1 to 3 Gy per fraction for 4 to 7 weeks for a total dose of 20 to 80 Gy.⁷⁹ The local recurrence rate (ie, tumor recurrence at the site that was irradiated) varied from 6.4% to 70%.⁷⁹ The 3-year recurrence rate was in the range of 60% to 67%,⁷⁹ whereas 5-year survival rates varied from 0% to 42%.^{80,81} Given these statistics, it is evident that conventional radiation therapy for early-stage NSCLC has a high local relapse rate and a low 5-year survival.⁷⁸ The patients who benefit most from conventional radiation therapy are those with smaller tumors and those who receive higher doses of radiation to the tumor.⁸⁰

Perhaps the greatest advancement in the past 10 years for early-stage NSCLC has been the use of stereotactic body radiation therapy (SBRT) in patients who are deemed medically inoperable or refuse surgery. SBRT is a method in which high doses of radiation (>15 Gy/fraction) are delivered to a tumor in 5 or fewer sessions over 1 to 2 weeks.⁸⁰ The radiation is transported via 6 to 12 radiation beams that all converge onto the tumor, which allows the targeting of a greater amount of radiation to the tumor while sparing the skin and normal surrounding lung tissue.⁸²

The Radiation Therapy Oncology Group recently published 3-year results on 55 patients with early-

stage NSCLC treated with SBRT.⁸³ They demonstrated that local control at 3 years was 90%, with a 3-year disease-free survival rate of 48%. The 3-year primary tumor control in this study was an impressive 97%, which is 2-fold greater than that of conventional radiation therapy.⁸³ There are some limitations to the use of SBRT. It is a newer treatment option that is not available in all centers and can only be done in tumors up to 5 cm, because the radiation dose becomes rate limiting. Furthermore, there is limited information on the relapse rate after 3 years. The largest trial to date has follow-up only out to 3 years.^{78,83} Another limitation is that SBRT cannot be used in centrally located tumors due to an 11-fold risk of developing severe radiation toxicity and increased risk of life-threatening bleeding compared with its relative safety in peripheral tumors.⁸⁴

Most studies that have been completed for SBRT for lung cancer have been performed in patients who are medically inoperable. Given the impressive short term SBRT results in patients with early-stage NSCLC, there is growing interest in studying its use in patients who are surgical candidates. There is an ongoing trial in the Netherlands randomizing patients to either surgery or SBRT for stage I NSCLC that examines local and regional control at 2 and 5 years. There is hope that this study will build on work already completed in Japan, in which a subgroup analysis showed that patients who were medically operable or refused surgery and who were treated with SBRT had a 5-year survival rate of 71%.^{85,86}

Table 2

Advantages and disadvantages of radiotherapy for early-stage lung cancer

Radiotherapy	Advantages	Disadvantages
1. Conventional radiation therapy	<ul style="list-style-type: none"> • Widely available 	<ul style="list-style-type: none"> • High relapse rate • Low 5-year survival • Requires 4–7 weeks for completion
2. Stereotactic body radiation therapy	<ul style="list-style-type: none"> • Completed within a few treatments • Good local control at 3 years • Can perform in patient with comorbid conditions • Can perform in patients who decline surgery • Can perform in tumors up to 5 cm in size 	<ul style="list-style-type: none"> • Limited data available on relapse rates after 3–5 years • Limited availability • Cannot perform in centrally located tumors
3. Radiofrequency ablation	<ul style="list-style-type: none"> • Completed in one session • Good local control at 2 years • Can perform in patients with comorbid conditions • Can perform in patients who decline surgery 	<ul style="list-style-type: none"> • Limited data available on relapse rates after 3–5 years • Limited availability • Best for tumors <3 cm in size • Cannot perform in centrally located tumors • High rate of pneumothorax

Table 3
Five-year survival and locoregional relapse rate after various therapies for early-stage non-small cell lung cancer

Treatment Modality	5-Year Survival	Locoregional Relapse Rate
Lobectomy	47%–90% ⁹²	2%–28% ^{14,26}
Segmentectomy	57%–85% ^{17,20}	8%–29% ^{14,92}
Wedge resection	27%–84% ^{17,20}	15%–55% ^{22,92}
Conventional radiotherapy	0%–42% ⁸¹	60%–67% ⁷⁹
Stereotactic body radiation therapy	48%–71% at 3 years ^{83,85}	22% at 3 years ⁸³
Radiofrequency ablation	48%–70% at 2 years ⁸⁷	25%–64% at 2 years ⁸⁷

Radiotherapy advances from the past decade also include the use of radiofrequency ablation (RFA) for treatment of lung tumors (see **Table 2** for a comparison of radiation therapy modalities). Despite no controlled studies that compare lung ablation with surgery or radiation, RFA has become more accepted. Performing RFA is similar to performing a CT-guided lung biopsy. Patients are placed in a CT scanner and sedated, and an RFA probe is placed into the tumor. The probe contains stainless steel electrodes that protrude outwards into the tumor; heat is transmitted to the tumor for a set amount of time (dependent on the size of the tumor) to achieve coagulation necrosis. Once the electrodes have cooled, the probe is removed and the track from the tumor to the skin is ablated to prevent bleeding and tumor cell dissemination.⁸⁷ Results depend on the size of the tumor, with 64% 2-year local control in tumors less than 3 cm in size but only 25% in tumors greater than 3 cm.⁸⁸ Although data are limited to small series, the overall survival with RFA at all stages at 1 year is 70% and at 2 years is 48%, both of which are superior to conventional radiation therapy.⁸⁷ The disadvantage of RFA is an approximately 30% rate of pneumothorax,^{89,90} related to the trocar and probe passing through normal lung tissue to reach the tumor. RFA is also limited by tumor size and location; tumors located within 1 cm of hilar structures are associated with increased risk of incomplete ablation and damage to bronchovascular structures, potentially leading to hemothorax.⁹¹ These considerations contribute to limited use of RFA for the treatment of NSCLC.

SUMMARY

Emerging from the past decade, there has been a diversification of options for the treatment of early-stage lung cancer (**Table 3**). VATS is now more widely performed, with oncologic outcomes equivalent to those with open thoracotomy.

Although lobectomy remains the standard approach to surgical resection, lesser resections, such as segmentectomy and wedge resection, are considerations for some patients. Advances in surgical, radiation, and medical therapies continue to evolve. Future research questions will focus on comparing long-term outcomes with these modalities, including survival, as well as patient-centered endpoints, such as quality of life.

REFERENCES

- Mountain CF. Revisions in the international system for staging lung cancer. *Chest* 1997;111(6):1710–7.
- Paolero PC, Williams DE, Bergstralh EJ, et al. Post-surgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. *Ann Thorac Surg* 1984;38(4):331–8.
- Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. *J Clin Oncol* 1984;2(12):1352–8.
- Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2(8):706–14.
- Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132(Suppl 3):234S–42S.
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer J Clin* 2010;60(5):277–300.
- The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365(5):395–409. [Epub ahead of print].
- Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North

- Central Cancer Treatment Group Study Groups. *J Clin Oncol* 2008;26(31):5043–51.
9. Graham EA. The first total pneumonectomy. *Tex Cancer Bull* 1949;2(1):2–4.
 10. Paul S, Port J. Limited resection for non-small cell lung cancer. *Chest Physician* 2010;5(6):13–4.
 11. Narsule CK, Ebright MI, Fernando HC. Sublobar versus lobar resection: current status. *Cancer J* 2011;17(1):23–7.
 12. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. *Ann Thorac Surg* 1995;60(3):615–22 [discussion: 622–23].
 13. Chang MY, Mentzer SJ, Colson YL, et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2007;134(4):850–6.
 14. El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. *Ann Thorac Surg* 2006;82(2):408–15 [discussion: 415–16].
 15. Errett LE, Wilson J, Chiu RC, et al. Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patients. *J Thorac Cardiovasc Surg* 1985;90(5):656–61.
 16. Pastorino U, Valente M, Bedini V, et al. Limited resection for Stage I lung cancer. *Eur J Surg Oncol* 1991;17(1):42–6.
 17. Miller DL, Rowland CM, Deschamps C, et al. Surgical treatment of non-small cell lung cancer 1 cm or less in diameter. *Ann Thorac Surg* 2002;73(5):1545–50 [discussion: 1550–51].
 18. Kondo D, Yamada K, Kitayama Y, et al. Peripheral lung adenocarcinomas: 10 mm or less in diameter. *Ann Thorac Surg* 2003;76(2):350–5.
 19. Schuchert MJ, Pettiford BL, Keeley S, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. *Ann Thorac Surg* 2007;84(3):926–32 [discussion: 932–933].
 20. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. *J Thorac Cardiovasc Surg* 2005;129(1):87–93.
 21. Landreneau RJ, Sugarbaker DJ, Mack MJ, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. *J Thorac Cardiovasc Surg* 1997;113(4):691–8 [discussion 698–700].
 22. Sienel W, Dango S, Kirschbaum A, et al. Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections. *Eur J Cardiothorac Surg* 2008;33(4):728–34.
 23. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. *Ann Surg Oncol* 2007;14(8):2400–5.
 24. Sawabata N, Ohta M, Matsumura A, et al. Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study. *Ann Thorac Surg* 2004;77(2):415–20.
 25. Warren WH, Faber LP. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. Five-year survival and patterns of intrathoracic recurrence. *J Thorac Cardiovasc Surg* 1994;107(4):1087–93 [discussion: 1093–94].
 26. Campione A, Ligabue T, Luzzi L, et al. Comparison between segmentectomy and larger resection of stage IA non-small cell lung carcinoma. *J Cardiovasc Surg (Torino)* 2004;45(1):67–70.
 27. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. *J Thorac Cardiovasc Surg* 1995;109(1):120–9.
 28. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer \leq 1 cm in size: a review of SEER data. *Chest* 2011;139(3):491–6.
 29. McKenna RJ Jr, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. *Ann Thorac Surg* 2006;81(2):421–5 [discussion: 425–6].
 30. Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. *World J Surg* 2000;24(1):27–30 [discussion: 30–1].
 31. Koizumi K, Haraguchi S, Hirata T, et al. Video-assisted lobectomy in elderly lung cancer patients. *Jpn J Thorac Cardiovasc Surg* 2002;50(1):15–22.
 32. Sakuraba M, Miyamoto H, Oh S, et al. Video-assisted thoracoscopic lobectomy vs. conventional lobectomy via open thoracotomy in patients with clinical stage IA non-small cell lung carcinoma. *Interact Cardiovasc Thorac Surg* 2007;6(5):614–7.
 33. Yamamoto K, Ohsumi A, Kojima F, et al. Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer. *Ann Thorac Surg* 2010;89(2):353–9.
 34. Shigemura N, Akashi A, Funaki S, et al. Long-term outcomes after a variety of video-assisted thoracoscopic lobectomy approaches for clinical stage IA lung cancer: a multi-institutional study. *J Thorac Cardiovasc Surg* 2006;132(3):507–12.
 35. Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. *J Clin Oncol* 2009;27(15):2553–62.
 36. Farjah F, Wood DE, Mulligan MS, et al. Safety and efficacy of video-assisted versus conventional lung resection for lung cancer. *J Thorac Cardiovasc Surg* 2009;137(6):1415–21.
 37. Inada K, Shirakusa T, Yoshinaga Y, et al. The role of video-assisted thoracic surgery for the treatment of

- lung cancer: lung lobectomy by thoracoscopy versus the standard thoracotomy approach. *Int Surg* 2000;85(1):6–12.
38. Sagawa M, Sato M, Sakurada A, et al. A prospective trial of systematic nodal dissection for lung cancer by video-assisted thoracic surgery: can it be perfect? *Ann Thorac Surg* 2002;73(3):900.
 39. Kirby TJ, Mack MJ, Landreneau RJ, et al. Lobectomy—video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial. *J Thorac Cardiovasc Surg* 1995;109(5):997–1001 [discussion: 1001–2].
 40. Handy JR Jr, Asaph JW, Douville EC, et al. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy? *Eur J Cardiothorac Surg* 2010;37(2):451–5.
 41. Ohbuchi T, Morikawa T, Takeuchi E, et al. Lobectomy: video-assisted thoracic surgery versus posterolateral thoracotomy. *Jpn J Thorac Cardiovasc Surg* 1998;46(6):519–22.
 42. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J Thorac Cardiovasc Surg* 2010;139(4):976–81 [discussion 981–3].
 43. Swanson SJ, Herndon JE 2nd, D'Amico TA, et al. Video-assisted thoracic surgery lobectomy: report of CALGB 39802—a prospective, multi-institution feasibility study. *J Clin Oncol* 2007;25(31):4993–7.
 44. Nagahiro I, Andou A, Aoe M, et al. Pulmonary function, postoperative pain, and serum cytokine level after lobectomy: a comparison of VATS and conventional procedure. *Ann Thorac Surg* 2001;72(2):362–5.
 45. Petersen RP, Pham D, Burfeind WR, et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. *Ann Thorac Surg* 2007;83(4):1245–9 [discussion: 1250].
 46. Yim AP, Landreneau RJ, Izzat MB, et al. Is video-assisted thoracoscopic lobectomy a unified approach? *Ann Thorac Surg* 1998;66(4):1155–8.
 47. Boffa DJ, Allen MS, Grab JD, et al. Data from the society of thoracic surgeons general thoracic surgery database: the surgical management of primary lung tumors. *J Thorac Cardiovasc Surg* 2008;135(2):247–54.
 48. Goodney PP, Lucas FL, Stukel TA, et al. Surgeon specialty and operative mortality with lung resection. *Ann Surg* 2005;241(1):179–84.
 49. Silvestri GA, Handy J, Lackland D, et al. Specialists achieve better outcomes than generalists for lung cancer surgery. *Chest* 1998;114(3):675–80.
 50. Schipper PH, Diggs BS, Ungerleider RM, et al. The influence of surgeon specialty on outcomes in general thoracic surgery: a national sample 1996 to 2005. *Ann Thorac Surg* 2009;88(5):1566–72 [discussion 1572–73].
 51. Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. *N Engl J Med* 2001;345(3):181–8.
 52. Lyons G, Quadrelli S, Silva C, et al. Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor. *J Thorac Oncol* 2008;3(9):989–93.
 53. Pelletier MP, Edwardes MD, Michel RP, et al. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. *Can J Surg* 2001;44(3):180–8.
 54. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. *Hematol Oncol Clin North Am* 1997;11(3):409–34.
 55. Sobin L, Wittekind C, editors. International union against cancer. Lung tumours. TNM classification of malignant tumors. New York: Wiley-Liss; 2002. p. 103.
 56. Carbone E, Asamura H, Takei H, et al. T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2001;122(5):907–12.
 57. Naruke T, Tsuchiya R, Kondo H, et al. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. *Ann Thorac Surg* 2001;71(6):1759–64.
 58. Mery CM, Pappas AN, Bueno R, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. *Chest* 2005;128(1):237–45.
 59. Sawada S, Komori E, Nogami N, et al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. *Chest* 2005;128(3):1557–63.
 60. Zapatero J, Flandes J, Salvatierra S, et al. Thoracotomy in patients over 70 years old. *Monaldi Arch Chest Dis* 1994;49(4):298–301.
 61. Okami J, Ito Y, Higashiyama M, et al. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. *Ann Thorac Surg* 2010;90(5):1651–6.
 62. Ikeda N, Hayashi A, Iwasaki K, et al. Surgical strategy for non-small cell lung cancer in octogenarians. *Respirology* 2007;12(5):712–8.
 63. Brokx HA, Visser O, Postmus PE, et al. Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. *J Thorac Oncol* 2007;2(11):1013–7.
 64. Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132:1S–19S.
 65. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis

- of the surveillance, epidemiologic, and end results database. *J Clin Oncol* 2006;24(28):4539–44.
66. Shepherd FA. Surgery for limited stage small cell lung cancer: time to fish or cut bait. *J Thorac Oncol* 2010;5(2):147–9.
 67. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? *Cancer* 2010;116(5):1350–7.
 68. Simon GR, Turrisi A, American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132(Suppl 3):324S–39S.
 69. Yu JB, Decker RH, Detterbeck FC, et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. *J Thorac Oncol* 2010;5(2):215–9.
 70. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. *BMJ* 1995;311(7010):899–909.
 71. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008;26(21):3552–9.
 72. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006;7(9):719–27.
 73. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med* 2005;352(25):2589–97.
 74. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. *N Engl J Med* 2004;350(4):351–60.
 75. Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIa resectable non small-cell lung cancer guideline. *J Clin Oncol* 2007;25(34):5506–18.
 76. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. *N Engl J Med* 1999;341(16):1198–205.
 77. Wisnivesky JP, Bonomi M, Henschke C, et al. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. *Chest* 2005;128(3):1461–7.
 78. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. *Int J Radiat Oncol Biol Phys* 2009;75(3):677–82.
 79. Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. *Lung Cancer* 2003;41(1):1–11.
 80. Powell JW, Dexter E, Scalzetti EM, et al. Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials. *Lancet Oncol* 2009;10(9):885–94.
 81. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. *Thorax* 2001;56(8):628–38.
 82. Nguyen NP, Garland L, Welsh J, et al. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. *Cancer Treat Rev* 2008;34(8):719–27.
 83. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. *JAMA* 2010;303(11):1070–6.
 84. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol* 2006;24(30):4833–9.
 85. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. *J Thorac Oncol* 2007;2(7 Suppl 3):S94–100.
 86. Onishi H, Shirato H, Nagata Y, et al. Stereotactic Body Radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? *Int J Radiat Oncol Biol Phys* 2010. [Epub ahead of print].
 87. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). *Lancet Oncol* 2008;9(7):621–8.
 88. Gewanter RM, Rosenzweig KE, Chang JY, et al. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. *Curr Probl Cancer* 2010;34(3):228–49.
 89. Steinke K, Sewell PE, Dupuy D, et al. Pulmonary radiofrequency ablation—an international study survey. *Anticancer Res* 2004;24(1):339–43.
 90. Lanuti M, Sharma A, Digumarthy SR, et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2009;137(1):160–6.
 91. Gomez FM, Palussiere J, Santos E, et al. Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed. *Clin Transl Oncol* 2009;11(1):28–34.
 92. Blasberg JD, Pass HI, Donington JS. Sublobar resection: a movement from the Lung Cancer Study Group. *J Thorac Oncol* 2010;5(10):1583–93.